Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Molecular Partners (MOLN) stocks

Learn how to easily invest in Molecular Partners stocks.

Molecular Partners is a biotechnology business based in the US. Molecular Partners stocks (MOLN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19 – an increase of 7.76% over the previous week. Molecular Partners employs 163 staff and has a trailing 12-month revenue of around $188.7 million.

How to buy Molecular Partners stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – MOLN. It's that simple.

Molecular Partners stock price (NASDAQ:MOLN)

Use our graph to track the performance of MOLN stocks over time.

Molecular Partners shares at a glance

Information last updated 2022-11-29.
Latest market close$7.08
52-week range$5.50 - $32.04
50-day moving average $6.39
200-day moving average $10.45
Wall St. target price$14.58
PE ratio 1.7063
Dividend yield $0 (0%)
Earnings per share (TTM) $3.78

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Interactive Brokers
Finder Rating:
4.1 / 5
min $1.00, max 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
National Bank Direct Brokerage
Finder Rating:
4.1 / 5
$0 if conditions met, or $100
Stocks, Bonds, Options, Mutual Funds, GICs
$0 commission on all transactions for Finder investors.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Finder Rating:
3.9 / 5
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $2,000 cashback + a $50 bonus on sign up. Use promo code CASHBONUS2023. Conditions apply. Ends March 1, 2023.

Compare up to 4 providers

Is it a good time to buy Molecular Partners stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Molecular Partners price performance over time

Historical closes compared with the close of $7.08 from 2022-12-01

1 week (2022-11-25) 7.76%
1 month (2022-11-02) 13.53%
3 months (2022-09-02) 22.28%
6 months (2022-06-02) 2.16%
1 year (2021-12-02) -47.94%
2 years (2020-12-02) -66.92%
3 years (2019-12-02) 16.5
5 years (2017-12-01) 24.7

Is Molecular Partners under- or over-valued?

Valuing Molecular Partners stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Molecular Partners's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Molecular Partners's P/E ratio

Molecular Partners's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Molecular Partners shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Molecular Partners's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    Molecular Partners's EBITDA

    Molecular Partners's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $116.6 million.

    The EBITDA is a measure of a Molecular Partners's overall financial performance and is widely used to measure a its profitability.

    To put Molecular Partners's EBITDA into context you can compare it against that of similar companies.

    Molecular Partners financials

    Revenue TTM $188.7 million
    Operating margin TTM 61.35%
    Gross profit TTM $-45,964,000
    Return on assets TTM 31.63%
    Return on equity TTM 62.46%
    Profit margin 62.2%
    Book value $7.73
    Market capitalisation $237.4 million

    TTM: trailing 12 months

    Molecular Partners share dividends

    We're not expecting Molecular Partners to pay a dividend over the next 12 months.

    Molecular Partners share price volatility

    Over the last 12 months, Molecular Partners's shares have ranged in value from as little as $5.5 up to $32.04. A popular way to gauge a stock's volatility is its "beta".

    MOLN.US volatility(beta: 0.75)Avg. volatility(beta: 1.00)LowHigh

    Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Partners's is 0.7539. This would suggest that Molecular Partners's shares are less volatile than average (for this exchange).

    To put Molecular Partners's beta into context you can compare it against those of similar companies.

    Molecular Partners overview

    Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc. ; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators.

    Frequently asked questions

    Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

    More on investing

    More guides on Finder

    Ask an Expert

    You must be logged in to post a comment.

    Go to site